Search results
...Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer with EGFR Exon 20...
ABC 26 New Orleans· 4 days agoSHANGHAI, April 24, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed...insertion (exon20ins) mutations will be presented at the 2024 American Society of Clinical ...
...Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented...
Morningstar· 4 days agoResults of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024 ...
AstraZeneca Plc (AZN) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 3 days agoNext slide, please. Our strong pipeline momentum has continued into 2024, we announced positive...
GE HealthCare expands Elekta collaboration By Investing.com
Investing.com· 6 days agoGE HealthCare (NASDAQ:GEHC) has announced an expanded collaboration with Elekta, a leader in...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 3 days agoPhase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback HB-200 accepted for oral abstract presentation
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for...
Benzinga· 4 days agoHOOKIPA Pharma Inc. HOOK ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Company has received clearance ...
Earnings call: Novartis reports strong Q1 with upgraded full-year guidance
Investing.com· 4 days agoNovartis AG (SIX: NOVN ) has delivered a robust financial performance in the first quarter of 2024,...